Clinical trials: Nonvalvular Atrial Fibrillation
Nonvalvular Atrial Fibrillation
TEE-Guided Versus CCTA-Guided Preprocedural Imaging for Left Atrial Appendage Closure
This prospective, open-label, multicenter randomized controlled trial will compare two preprocedural imaging assessment strategies in adults with nonvalvular atrial fibrillation who are scheduled to undergo percutaneous left…
- Trial name
- PEARL-LAAC (NCT07815119)
- Testing
- Transesophageal Echocardiography-Guided Preprocedural Assessment, Cardiac Computed Tomography Angiography-Guided Preprocedural Assessment
- Where
- China
- Volunteers
- 590 people
- Sponsor
- Shanghai Zhongshan Hospital
Nonvalvular Atrial Fibrillation, Severe Degenerative Mitral Regurgitation
Watchman for Patients With Atrial Fibrillation Undergoing Transcatheter Mitral Valve Repair (WATCH-TMVR)
WATCH-TMVR (Watchman for Patients with Atrial Fibrillation Undergoing Transcatheter Mitral Valve) Clinical Trial have the main objective to assess the feasibility of combining clinically indicated MitraClip TMVR and Watchman LAAO…
- Trial name
- WATCH-TMVR (NCT04494347)
- Testing
- MitraClip TMVR and Watchman LAAO
- Where
- 2 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Nonvalvular Atrial Fibrillation
Apixaban Safety and Therapy Adherence in Patients With Atrial Fibrillation
The aim of this observational study is to evaluate safety and therapeutic adherence during anticoagulant prophylaxis with apixaban in patients with nonvalvular atrial fibrillation.
- Trial name
- NCT07458191
- Testing
- Apixaban
- Where
- Bosnia and Herzegovina
- Volunteers
- 800 people
- Sponsor
- Bosnalijek D.D
Nonvalvular Atrial Fibrillation
Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (> 80 Years) With Atrial FIbrillation in a Prospective reAl World Study;
The main objective of this study is to realize an observational "real life" study conducted in French geriatric settings, to assess safety and efficacy in ≥ 80 year-old patients with nonvalvular Atrial fibrillation (AF) newly…
- Trial name
- SOFIA (NCT04586972)
- Where
- France
- Volunteers
- 977 people
- Sponsor
- Gérond'if
Nonvalvular Atrial Fibrillation, Aspirin
Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure
The goal of this clinical trial is to verify that Non-Antithrombotic Therapy (NAPT) followed by Oral Anticoagulants (OAC) monotherapy for 45 days after Left Atrial Appendage Closure (LAAC) is non-inferior to Single Antiplatelet…
- Conditions
- Nonvalvular Atrial Fibrillation, Aspirin, Non-Antithrombotic Therapy, High Bleeding Risk
- Trial name
- NCT07125417
- Testing
- Single Antiplatelet Therapy or No Therapy (Control), Non-Antithrombotic Therapy
- Where
- 21 sites in Japan
- Volunteers
- 500 people
- Sponsor
- OCEAN-SHD Study Group
Nonvalvular Atrial Fibrillation
First in Man Study of Left Atrial Appendage Pulsed Field Ablation Occluder
This is the first in man study of E-SeaLATM developed and manufactured by Hangzhou Dinova EP Technology Co., Ltd, which can achieve pulsed field ablation and mechanical closure of the Left Atrial Appendage simultaneously, this…
- Trial name
- NCT05731882
- Testing
- E-SeaLA, CardioPulse PFA system
- Where
- 3 sites in China
- Volunteers
- 10 people
- Sponsor
- Hangzhou Dinova EP Technology Co., Ltd
Nonvalvular Atrial Fibrillation, Health, Subjective
Pharmacokinetic Study to Evaluate Dabigatran Etexilate in Elderly Subjects
This study intends to collect blood samples of adult healthy subjects, elderly healthy subjects and elderly patients with atrial fibrillation after taking dabigatran etexilate for pharmacokinetics and other studies, aiming to…
- Trial name
- NCT05715658
- Testing
- Dabigatran etexilate capsule
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dongyang Liu
Nonvalvular Atrial Fibrillation
Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation
The purpose of this study is to establish a benchmark for rate of prescription of oral anticoagulants (OA) in patients with non-valvular atrial fibrillation (NVAF) seen in an ambulatory care setting, based on independent medical…
- Trial name
- BOAT-AF (NCT02919982)
- Where
- 21 sites in United States
- Volunteers
- 817 people
- Sponsor
- Baim Institute for Clinical Research
Nonvalvular Atrial Fibrillation
AntiCoagulants and COGnition
The purpose of this study is to compare the change of global cognitive performance after 52 weeks of intervention among participants with nonvalvular atrial fibrillation (NVAF) receiving rivaroxaban versus a vitamin K antagonist…
- Trial name
- ACCOG (NCT04073316)
- Testing
- Rivaroxaban 20 MG, Warfarin
- Where
- France
- Volunteers
- 48 people
- Sponsor
- University Hospital, Angers
NonValvular Atrial Fibrillation
Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation
The primary objectives of this study are: To estimate the incidence rate of unexpected adverse events To characterize the bleeding events and assess risk factors of bleeding To identify ancillary baseline variables that may also…
- Trial name
- NCT02007655
- Testing
- Eliquis
- Where
- Japan
- Volunteers
- 6,372 people
- Sponsor
- Bristol-Myers Squibb
Nonvalvular Atrial Fibrillation
The Adherence to Oral Anticoagulant in Chinese Patients With NVAF
Investigate the compliance of oral anticoagulants in Chinese NVAF patients and find out the causes, so as to provide basis for formulating effective measures to improve the compliance of oral anticoagulants.
- Trial name
- NVAF (NCT04942873)
- Testing
- adherence
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Nonvalvular Atrial Fibrillation
Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients
The overall goal of this study was to evaluate the comparative safety and effectiveness of rivaroxaban vs. vitamin K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) across risk…
- Trial name
- NCT03374540
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- United States
- Volunteers
- 78,517 people
- Sponsor
- Bayer
NonValvular Atrial Fibrillation
Eliquis Regulatory Post Marketing Surveillance
The primary objective of this study is to examine the safety profile of Eliquis in Korean nonvalvular atrial fibrillation patients.
- Trial name
- NCT01885598
- Testing
- Apixaban
- Where
- South Korea
- Volunteers
- 3,335 people
- Sponsor
- Bristol-Myers Squibb
Persistent Nonvalvular Atrial Fibrillation
Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation
- Trial name
- NCT00171769
- Testing
- Certoparin
- Where
- 2 sites in United States, Germany
- Volunteers
- 200 people
- Sponsor
- Novartis
Nonvalvular Atrial Fibrillation
Evaluation of Hospital Readmissions Among Hospitalized Non-valvular Atrial Fibrillation (NVAF) Patients in the US
The overall objective of this proposal is to execute a real-world database analysis to evaluate hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients in the U.S Primary objective: To determine…
- Trial name
- NCT02674594
- Volunteers
- 30,000 people
- Sponsor
- Bristol-Myers Squibb
Persistent or Permanent Nonvalvular Atrial Fibrillation
Long-term Safety in Atrial Fibrillation Patients
The purpose of this study is to provide safety and tolerability data for AZD0837 during long-term treatment (5 years) in patients with non-valvular atrial fibrillation (AF) and one or more additional risk factors for stroke and…
- Trial name
- NCT00645853
- Testing
- AZD0837, VKA INR 2-3
- Volunteers
- 523 people
- Sponsor
- AstraZeneca
Nonvalvular Atrial Fibrillation
Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation
The main purpose of this study is to provide dose-guiding information by assessing the safety and tolerability of 4 different dosing regimens of an extended-release (ER) formulation of AZD0837 compared with well-controlled…
- Trial name
- NCT00684307
- Testing
- AZD0837, Vitamin-K antagonist at INR 2-3
- Volunteers
- 1,084 people
- Sponsor
- AstraZeneca